NEW YORK, April 6 (GenomeWeb News) - Genomics Collaborative and Cybrdi will co-develop a breast tumor tissue microarray, the companies said today.
The arrays will be accompanied by clinical data on the molecular factors of the tissue to "establish correlations between the severity of the disease, responses to treatments, and the presence of certain biomarkers," Larry Liu, president and CEO of Cybrdi, said in the statement. "It can be expanded to other types of malignancies, including colon, lung, and brain tumors."
Genomics Collaborative, a division of SeraCare Life Science, is providing tissue from its GC Global Repository samples, which are linked to clinical, demographic, and treatment data.
"We hope to generate additional tumor-specific tissue arrays that look at the tissue's response to treatment," said Kevin Krenitsky, Genomics Collaborative senior vice president, in the statement.